Liver disease as a major cause of death among HIV infected patients:: role of hepatitis C and B viruses and alcohol

被引:243
作者
Salmon-Ceron, D
Lewden, C
Morlat, P
Bévilacqua, S
Jougla, E
Bonnet, F
Héripret, L
Costagliola, D
May, T
Chêne, G
机构
[1] Hop Cochin, Dept Internal Med, F-75674 Paris, France
[2] Univ Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France
[3] St Andre Hosp, Dept Internal Med, F-33075 Bordeaux, France
[4] Brabois Hosp, Infect & Trop Dis Dept, F-54511 Vandoeuvre Les Nancy, France
[5] INSERM, CepiDc, F-78116 Le Vesinet, France
[6] Archet Hosp, Infect & Trop Dis Dept, F-06202 Nice, France
[7] Univ Paris 06, INSERM, EPI 0214, F-75625 Paris, France
关键词
HIV infection; hepatitis B; hepatitis C; causes of death; AIDS; mortality; HAART; hepatocellular carcinoma;
D O I
10.1016/j.jhep.2005.01.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection. Methods: One-hundred and eighty-five French hospital departments involved in HIV/AIDS management prospectively notified all deaths occurring in 2000. Patients whose hepatitis C (HCV) and hepatitis B (HBV) serostatus was known were classified as being infected by HCV alone, HBV alone (HBsAg positive), both HCV and HBV, or neither HCV nor HBV. Results: Among 822 HIV infected patients, 29% were infected by HCV alone, 8% by HBV alone, and 4% by both HCV and HBV. The most frequent causes of death were liver disease (31% of cases) and AIDS (29%) among HIV-HCV co-infected patients, and AIDS (38%) and liver disease (22%) among HIV-HBV co-infected patients. Liver disease was a more frequent cause of death among patients co-infected by both HCV and HBV (44% of cases). Hepatocellular carcinoma was present in 15% of patients who died from liver disease, and was associated with HBV co-infection. Nearly half the patients who died from liver disease had more than 200 CD4/mm(3). Conclusions: Liver disease is now a leading cause of death among HIV-HCV co-infected patients and is becoming an important cause of death among HIV-HBV co-infected patients. The risk of death from liver disease is highest in patients co-infected by both HCV and HBV. (C) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:799 / 805
页数:7
相关论文
共 26 条
[1]   Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].
Alberti, A ;
Clumeck, N ;
Collins, S ;
Gerlich, W ;
Lundgren, J ;
Palù, G ;
Reiss, P ;
Thiebaut, R ;
Weiland, O ;
Yazdanpanah, Y ;
Zeuzem, S .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624
[2]  
[Anonymous], 1993, INT CLASS DIS
[3]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[4]   Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].
Benhamou, Y ;
Bochet, M ;
Di Martino, V ;
Charlotte, F ;
Azria, F ;
Coutellier, A ;
Vidaud, M ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (04) :1054-1058
[5]   Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].
Carrat, F ;
Bani-Sadr, F ;
Pol, S ;
Rosenthal, E ;
Lunel-Fabiani, F ;
Benzekri, A ;
Morand, P ;
Goujard, C ;
Pialoux, G ;
Piroth, L ;
Salmon-Céron, D ;
Degott, C ;
Cacoub, P ;
Perronne, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848
[6]  
CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9
[7]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[8]   Etiology, natural history and treatment of hepatocellular carcinoma [J].
Colombo, M ;
Sangiovanni, A .
ANTIVIRAL RESEARCH, 2003, 60 (02) :145-150
[9]  
Conti S, 2002, J ACQ IMMUN DEF SYND, V29, P105
[10]   HIGH HEPATITIS-C VIREMIA AND IMPAIRED ANTIBODY-RESPONSE IN PATIENTS COINFECTED WITH HIV [J].
CRIBIER, B ;
REY, D ;
SCHMITT, C ;
LANG, JM ;
KIRN, A ;
STOLLKELLER, F .
AIDS, 1995, 9 (10) :1131-1136